Segall Bryant & Hamill’s Anixa Biosciences ANIX Stock Holding History

Segall Bryant & Hamill’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-17,400	Closed	-$55.7K	–	519
2023 Q2	$55.7K	Hold	17,400	–	–	﹤0.01%	700
2023 Q1	$74K	Hold	17,400	–	–	﹤0.01%	706
2022 Q4	$73K	Hold	17,400	–	–	﹤0.01%	705
2022 Q3	$86K	Hold	17,400	–	–	﹤0.01%	713
2022 Q2	$53K	Hold	17,400	–	–	﹤0.01%	719
2022 Q1	$48K	Hold	17,400	–	–	﹤0.01%	739
2021 Q4	$52K	Hold	17,400	–	–	﹤0.01%	592
2021 Q3	$83K	Hold	17,400	–	–	﹤0.01%	773
2021 Q2	$68K	Hold	17,400	–	–	﹤0.01%	759
2021 Q1	$82K	Hold	17,400	–	–	﹤0.01%	806
2020 Q4	$53K	Hold	17,400	–	–	﹤0.01%	730
2020 Q3	$43K	Hold	17,400	–	–	﹤0.01%	703
2020 Q2	$53K	Hold	17,400	–	–	﹤0.01%	769
2020 Q1	$27K	Hold	17,400	–	–	﹤0.01%	776
2019 Q4	$57K	Hold	17,400	–	–	﹤0.01%	810
2019 Q3	$70K	Hold	17,400	–	–	﹤0.01%	809
2019 Q2	$64K	Hold	17,400	–	–	﹤0.01%	804
2019 Q1	$79K	Hold	17,400	–	–	﹤0.01%	809
2018 Q4	$69K	Hold	17,400	–	–	﹤0.01%	806
2018 Q3	$81K	Hold	17,400	–	–	﹤0.01%	832
2018 Q2	$53K	Buy	+17,400	New	+$64.5K	﹤0.01%	847

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MWM

Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Segall Bryant & Hamill's ANIX Position: Q3 2023 in Review

Segall Bryant & Hamill sold out of Anixa Biosciences (ANIX) in Q3 2023, closing a stake of 17,400 shares — an estimated $55.7K sold.

Segall Bryant & Hamill first reported a position in ANIX in Q2 2018 and held it in 21 quarters. The position peaked at $86K in Q3 2022. 49 funds tracked by Wall St. Rank hold ANIX as of Q3 2023.

Segall Bryant & Hamill reported no remaining Anixa Biosciences position as of Q3 2023 after selling out during the quarter.
Segall Bryant & Hamill sold 17,400 Anixa Biosciences shares in Q3 2023, an estimated $55.7K.
Segall Bryant & Hamill first reported a position in Anixa Biosciences in Q2 2018 and held it in 21 quarters.
Segall Bryant & Hamill's Anixa Biosciences position peaked at $86K in Q3 2022.
49 funds tracked by Wall St. Rank held Anixa Biosciences as of Q3 2023.

Based on Segall Bryant & Hamill's 13F filing for Q3 2023, filed 9 Nov 2023.